Abstract
Human leukocyte antigen G (HLA-G) is a non-classic major histocompatibility complex (MHC) class I molecule that functions as an immune suppressive molecule. HLA-G has direct inhibitory effects on natural killer cells (NK), dendritic cells (DC), T cells and has long-term tolerogenic indirect effects by inducing regulator T cells (Treg). HLA-G has been reported to be involved in various physio-pathological conditions such as reproduction, transplantation, autoimmunity, infectious and malignant diseases. In this context, aberrant expression of HLA-G in malignant diseases including hematological and solid tumors has been extensively investigated and its relevance to clinicoparameters and potential significance in diagnosis, prognosis and immune target therapy has been postulated. We here summarized the HLA-G expression in malignancies and emphasis its clinical relevance to malignant disease diagnosis, prognosis, and its potential in target-based immunotherapy was also discussed.
Keywords: HLA-G, malignancies, diagnosis, prognosis, immunotherapy, b2-microglobulin, trogocytosis, cytotrophoblasts, cutaneous melanoma, glioblastoma multiforme, hydatiform moles
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy
Volume: 11 Issue: 1
Author(s): Wei-Hua Yan
Affiliation:
Keywords: HLA-G, malignancies, diagnosis, prognosis, immunotherapy, b2-microglobulin, trogocytosis, cytotrophoblasts, cutaneous melanoma, glioblastoma multiforme, hydatiform moles
Abstract: Human leukocyte antigen G (HLA-G) is a non-classic major histocompatibility complex (MHC) class I molecule that functions as an immune suppressive molecule. HLA-G has direct inhibitory effects on natural killer cells (NK), dendritic cells (DC), T cells and has long-term tolerogenic indirect effects by inducing regulator T cells (Treg). HLA-G has been reported to be involved in various physio-pathological conditions such as reproduction, transplantation, autoimmunity, infectious and malignant diseases. In this context, aberrant expression of HLA-G in malignant diseases including hematological and solid tumors has been extensively investigated and its relevance to clinicoparameters and potential significance in diagnosis, prognosis and immune target therapy has been postulated. We here summarized the HLA-G expression in malignancies and emphasis its clinical relevance to malignant disease diagnosis, prognosis, and its potential in target-based immunotherapy was also discussed.
Export Options
About this article
Cite this article as:
Yan Wei-Hua, HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy, Endocrine, Metabolic & Immune Disorders - Drug Targets 2011; 11 (1) . https://dx.doi.org/10.2174/187153011794982059
DOI https://dx.doi.org/10.2174/187153011794982059 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting the Bone Microenvironment in Metastatic Castration-Resistant Prostate Cancer
Current Drug Targets The Past, Current Studies and Future of Organometallic <sup>99m</sup>Tc(CO)3 Labeled Peptides and Proteins
Current Pharmaceutical Design Current Perspectives on Novel Drug Delivery Systems and Therapies for Management of Prostate Cancer: An Inclusive Review
Current Drug Targets Protein Transduction Domains: Applications for Molecular Medicine
Current Gene Therapy Proteomics as a Tool in the Pharmaceutical Drug Design Process
Current Pharmaceutical Design Anticancer Potential of Ginger: Mechanistic and Pharmaceutical Aspects
Current Pharmaceutical Design New Optical Molecular Imaging Systems
Current Pharmaceutical Biotechnology FADS1 is a Prognostic Biomarker in Bladder Cancer: A Study Based on TCGA Data
Combinatorial Chemistry & High Throughput Screening Diffusion-Weighted Magnetic Resonance Imaging in Pelvic Cancer
Current Medical Imaging Ceramic Nanoparticles: Fabrication Methods and Applications in Drug Delivery
Current Pharmaceutical Design Immunomodulation in Inflammatory Neuropathies: Rationale and Safety
Current Drug Safety Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases
Current Genomics E2F1 and NF-κB: Key Mediators of Inflammation-associated Cancers and Potential Therapeutic Targets
Current Cancer Drug Targets Mitochondrial Proteases as Emerging Pharmacological Targets
Current Pharmaceutical Design Regulation of EMT by Notch Signaling Pathway in Tumor Progression
Current Cancer Drug Targets Bugs as Drugs: Understanding the Linkage between Gut Microbiota and Cancer Treatment
Current Drug Targets The Role for Oxidative Stress in Aberrant DNA Methylation in Alzheimer’s Disease
Current Alzheimer Research Medicinal Plants and Cancer Chemoprevention
Current Drug Metabolism Pharmacological Inhibitors of NAD Biosynthesis as Potential An ticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Phosphodiesterase Inhibitors as a Target for Cognition Enhancement in Aging and Alzheimer’s Disease: A Translational Overview
Current Pharmaceutical Design